Thermo Fisher Launches Gibco VaxEvo CD 293 Medium
The chemically defined, animal origin-free medium targets high-titer adenovirus production for vaccine developers.
Updated on Nov. 19, 2026 in Biotech

Thermo Fisher Scientific has launched Gibco VaxEvo CD 293 Medium, a chemically defined, animal origin-free medium designed to support suspension HEK293 cell growth and high-titer adenovirus production. The product is available in liquid and AGT formats.
Why it matters
Vaccine developers need media that deliver strong productivity while reducing process complexity and supporting manufacturing readiness. The launch targets that need across development, scale-up and manufacturing.
Benchmarking studies using HEK293 cells found average adenovirus type 5 titers comparable to select supplier media, with some comparisons reaching up to 5.7-fold higher titers. The extraction does not detail the study count, the benchmark media used, or results beyond these comparisons.
The players
Thermo Fisher Scientific
Thermo Fisher Scientific is a major American life sciences company that supplies laboratory, biotechnology and manufacturing products worldwide.
The details
The medium is designed to support vaccine developers from early process development through scale-up and manufacturing. In benchmarking studies, it showed comparable or higher titers without a dedicated feed versus select benchmark media used with their recommended feeds.
Timeline
November 19, 2026: Thermo Fisher announced the medium launch.
The Tech Race
The launch positions Thermo Fisher's media against other suppliers serving HEK293-based adenovirus vector manufacturing, a segment where titer yield and process simplicity drive product competition. Animal origin-free, chemically defined formulations have become a standard expectation for vaccine manufacturers seeking regulatory consistency.
For vaccine developers, the medium offers an option to pursue high adenovirus titers without a dedicated feed, which may simplify process design. Readers outside the manufacturing sector are unlikely to see direct effects from this product launch.
The takeaway
Developers evaluating adenovirus production media can compare chemically defined, animal origin-free options against their current process needs. Benchmarking data on titer performance offers a starting point for that comparison.
Further reading
Explore more Biotech coverage for context on cell culture and vaccine manufacturing advances.
More information
Details are available on the Gibco VaxEvo CD 293 Medium product page.
Source note: This article includes information reported by Pharmafocusasia.



